[go: up one dir, main page]

WO2025040355A1 - Composition de soins personnels - Google Patents

Composition de soins personnels Download PDF

Info

Publication number
WO2025040355A1
WO2025040355A1 PCT/EP2024/070948 EP2024070948W WO2025040355A1 WO 2025040355 A1 WO2025040355 A1 WO 2025040355A1 EP 2024070948 W EP2024070948 W EP 2024070948W WO 2025040355 A1 WO2025040355 A1 WO 2025040355A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
compound
carboxymethyl cysteine
composition according
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/070948
Other languages
English (en)
Inventor
Xuelan GU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2025040355A1 publication Critical patent/WO2025040355A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/447—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C

Definitions

  • the present invention relates to a personal care composition
  • a personal care composition comprising carboxymethyl cysteine compound and vitamin C compound, wherein the molar ratio of the carboxymethyl cysteine compound to the vitamin C compound is at least 14:1. It was unexpectedly found that such composition is capable of significantly upregulating the expression of OR10A6 (Olfactory Receptor Family 10 Subfamily A Member 6) gene.
  • OR10A6 Olefactory Receptor Family 10 Subfamily A Member 6
  • Skin is an organ that protects the body from external stressors like heat, UV, pollutants, allergens, pathogens etc. It also prevents loss of moisture.
  • the protective role of skin is carried out by epidermal or skin barrier.
  • the skin barrier consists of different layers of stratified cells and the outermost layer consists of corneocytes embedded in a layer of lipids.
  • OR10A6 are involved in epidermal differentiation, water-impermeable barrier homeostasis, and stress response mechanisms (Shinobu Nakanishi et al., Frontiers in Cell and Developmental Biology, 11 :1102585. doi: 10.3389/fcell.2023.1102585; Romain Duroux et al., Molecules 2020, 25, 4743; doi:10.3390/molecules25204743).
  • OR10A6 may be a potential target for modulation of keratinization, to provide benefits of stress reduction, strengthening skin barrier.
  • the present invention is directed to a personal care composition
  • a personal care composition comprising carboxymethyl cysteine compound and vitamin C compound, wherein the molar ratio of the carboxymethyl cysteine compound to the vitamin C compound is at least 14:1 , wherein the composition comprises water in amount of 10 to 96% by weight of the composition.
  • the present invention is directed to a method of providing the skin benefits selected from the group consisting of improving skin barrier health, strengthening skin barrier, and stress reduction comprising a step of topically applying to the skin the composition of the present invention.
  • the present invention is directed to use of the composition of the present invention for providing the skin benefits selected from the group consisting of improving skin barrier health, strengthening skin barrier, and stress reduction.
  • the carboxymethyl cysteine compound refers to compound selected from carboxymethyl cysteine, salt of carboxymethyl cysteine, ester of carboxymethyl cysteine, amide of carboxymethyl cysteine or a mixture thereof.
  • the carboxymethyl cysteine compound comprises carboxymethyl cysteine, ester of carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  • the carboxymethyl cysteine compound comprises carboxymethyl cysteine, and/or salt of carboxymethyl cysteine.
  • carboxymethyl cysteine compound comprises salt of carboxymethyl cysteine.
  • the carboxymethyl cysteine compound comprises lysine carboxymethyl cysteinate and most preferably, the carboxymethyl cysteine compound is lysine carboxymethyl cysteinate.
  • the carboxymethyl cysteine compound is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001%, still even more preferably at least 0.01%, and most preferably at least 0.1 % by weight of the composition.
  • the carboxymethyl cysteine compound is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of no greater than 10%, more preferably no greater than 5%, even more preferably no greater than 3%, still even more preferably no greater than 1 %, and most preferably no greater than 0.5% by weight of the composition.
  • the lysine carboxymethyl cysteinate is present in amount of at least 0.00001%, more preferably at least 0.0001 %, even more preferably at least 0.001 %, still even more preferably at least 0.01 %, and most preferably at least 0.1 % by weight of the composition.
  • the vitamin C compound refers to compound selected from ascorbic acid (also known as vitamin C), salt, ester, and ether thereof. Any physiologically acceptable salt of ascorbic acid may be used. Salts of ascorbic acid comprise alkali metal, alkaline earth metal salts, ammonium salt, those derived from monoethanolamine, diethanolamine, amino acids salt such as arginine or lysine, or combination thereof. Suitable ascorbic acid esters are those in which one or more hydroxy groups in the 2-, 3-, 5- and/or 6-positions are fatty acid ester, sulphate or phosphate.
  • the Vitamin C compound is ester of ascorbic acid. More preferably the vitamin C compound is ascorbyl phosphate. Still even more preferably, vitamin C compound is magnesium ascorbyl phosphate and/or sodium ascorbyl phosphate.
  • the vitamin C compound comprises ascorbic acid, calcium ascorbate dihydrate, sodium ascorbate, ascorbyl glycoside, glyceryl ascorbate, 3-O-ethyl-L-ascorbic acid, methoxy peg-7 ascorbic acid, ascorbyl stearate, ascorbyl tetraisopalmitate, tetrahexyldecyl ascorbate, ascorbyl phosphate, ascorbyl palmitate, or a mixture thereof.
  • the vitamin C compound comprises ascorbic acid, ascorbyl phosphate, sodium ascorbate, ascorbyl glucoside, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Even more preferably, the vitamin C compound comprises ascorbic acid, ascorbyl phosphate, ascorbyl glucoside, glyceryl ascorbate, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Even more preferably, the vitamin C compound comprises ascorbyl phosphate, ascorbyl glucoside, ascorbyl tetraisopalmitate, ascorbyl palmitate, or a mixture thereof. Still even more preferably, the vitamin C compound comprises ascorbyl phosphate.
  • the amount of the vitamin C compound of the is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1 .2% by weight of the composition.
  • the amount of ester of ascorbic acid is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1.2% by weight of the composition.
  • the amount of ascorbyl phosphate is 0.0001 to 8% by weight of the composition, more preferably 0.005 to 5% by weight, even more preferably 0.02 to 2% and most preferably 0.1 to 1 .2% by weight of the composition.
  • the molar ratio of the carboxymethyl cysteine compound to the vitamin C compound is 14:1 to 500:1 , more preferably 14:1 to 200:1 , even more preferably 15:1 to 70:1 , still even more preferably 16:1 to 30:1.
  • the molar ratio of the carboxymethyl cysteine compound to ester of ascorbic acid is 14:1 to 500:1 , more preferably 14:1 to 200:1, even more preferably 15:1 to 70:1 , still even more preferably 16:1 to 30:1.
  • the molar ratio of the carboxymethyl cysteine compound to ascorbyl phosphate acid is 14:1 to 500:1 , more preferably 14:1 to 200:1 , even more preferably 15:1 to 70:1 , still even more preferably 16:1 to 30:1.
  • the molar ratio of the lysine carboxymethyl cysteinate to ascorbyl phosphate acid is 14:1 to 500:1 , more preferably 14:1 to 200:1 , even more preferably 15:1 to 70:1 , still even more preferably 16:1 to 30:1.
  • the composition may optionally comprise whitening pigment.
  • Whitening pigments are typically particles of high refractive index materials.
  • the whitening pigment may have a refractive index of greater than 1.3, more preferably greater than 1.8 and most preferably from 2.0 to 2.7.
  • Examples of such whitening pigment are those comprising bismuth oxy-chloride, boron nitride, barium sulfate, mica, silica, titanium dioxide, zirconium oxide, aluminium oxide, zinc oxide or combinations thereof. More preferred whitening pigment are particles comprising titanium dioxide, zinc oxide, zirconium oxide, mica, iron oxide or a combination thereof.
  • Even more preferred whitening pigment are particles comprising zinc oxide, zirconium oxide, titanium dioxide or a combination thereof as these materials have especially high refractive index. Still even more preferably the whitening pigment is selected from titanium dioxide, zinc oxide or a mixture thereof and most preferred whitening pigment is titanium dioxide.
  • the average diameter of whitening pigment is typical from 15 nm to 1 micron, more preferably from 35 nm to 800 nm, even more preferably from 50 nm to 500 nm and still even more preferably from 100 to 300 nm.
  • Amount of whitening pigment may be 0.1 to 15%, preferably 0.5 to 5% by weight of the composition.
  • the composition comprises a glutamate source selected from the group consisting of glutamine, glutamine ester, glutamic acid, pyroglutamic acid, salts, and mixtures thereof. More preferably, the composition comprises pyroglutamic acid and/or salt of pyroglutamic acid. Even more preferably, the composition comprises sodium salt of pyroglutamic acid.
  • the glutamate source is present in amount of 0.0001 to 10% by weight of the composition, more preferably 0.001 to 6%, even more preferably 0.01 to 3% by weight of the composition.
  • the composition comprises polyhydric alcohol.
  • Polyhydric alcohols may be selected from group of glycerin, propylyene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1 ,3-butylene glycol, isoprene glycol, ethoxylated glycerol, propoxylated glycerol or a mixture thereof.
  • Most preferred polyhydric alcohol is glycerol known also as glycerin.
  • the amount of polyhydric alcohol may range anywhere from 0.1 to 20%, preferably 0.5 to 15% and more preferably 2 and 10% by weight of the composition.
  • the composition comprises emollient materials.
  • Suitable emollient materials include silicones, hydrocarbons, triglycerides or a mixture thereof. These silicones may be organic, silicone-containing or fluorine-containing, volatile or non-volatile, polar or non-polar. Hydrocarbons may include mineral oil, petrolatum and polyalpha-olefins. Examples of preferred volatile hydrocarbons include polydecanes such as isododecane and isodecane (e.g. Permethyl- 99A which is available from Presperse Inc.) and the C7-C8 through C12-C15 isoparaffins (such as the Isopar Series available from Exxon Chemicals).
  • Illustrative triglycerides but not limiting are sunflower seed oil, cotton oil, canola oil, soybean oil, castor oil, borage oil, olive oil, shea butter, jojoba oil and mixtures thereof. Mono- and di- glycerides may also be useful. Particularly preferable are glyceryl monostearate and glyceryl distearate.
  • the composition comprises moisturizing agents.
  • moisturizing agents includes, petrolatum, aquaporin manipulating actives, oat kernel flour, substituted urea like hydroxyethyl urea, hyaluronic acid and/or its precursor N-acetyl glucosamine, hyaluronic acid and/or its precursor N-acetyl glucosamine, or a mixture thereof.
  • compositions may include thickeners. These may be selected from cellulosics, natural gums and acrylic polymers but not limited by this thickening agent types.
  • cellulosics sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose and combinations thereof.
  • Suitable gums include xanthan, pectin, karaya, agar, alginate gums and combinations thereof.
  • acrylic thickeners are homopolymers and copolymers of acrylic and methacrylic acids including carbomers such as Carbopol 1382, Carbopol 982, llltrez, Aqua SF-1 and Aqua SF-2 available from the Lubrizol Corporation.
  • Amounts of thickener may range from 0.01 to 3% by weight of the active polymer (outside of solvent or water) in the compositions.
  • compositions of the invention may further include 0.5 to 10% by weight of sequestering agents, such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures; opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • sequestering agents such as tetra sodium ethylenediaminetetraacetate (EDTA), EHDP or mixtures
  • opacifiers and pearlizers such as ethylene glycol distearate, titanium dioxide or Lytron 621 (Styrene/Acrylate copolymer); all of which are useful in enhancing the appearance or properties of the product.
  • the composition comprise water in amount of 10 to 96% by weight of the composition, more preferably from 25 to 92%, even more preferably from 42 to 88%, most preferably from 55 to 82% by weight of the composition.
  • the composition has a viscosity of at least 10 mPa s, more preferably in the range 30 to 10000 mPa s, even more preferably 50 to 5000 mPa s, and most preferably 100 to 2000 mPa s, when measured at 20 degrees C at a relatively high shear rate of about 20 s' 1 .
  • the composition is an emulsion, more preferably an oil-in-water emulsion.
  • the composition is a fluid liquid at 25 °C and atmospheric pressure.
  • the composition is capable of upregulating the expression of OR10A6 (Olfactory Receptor Family 10 Subfamily A Member 6) gene by at least 1.2 fold change, more preferably 1.2 to 4, and even more preferably 1.3 to 3 fold change, typically in comparison to personal care composition comprising neither carboxymethyl cysteine compound nor vitamin C compound.
  • OR10A6 Olefactory Receptor Family 10 Subfamily A Member 6
  • the use is non-therapeutic.
  • the method is non-therapeutic.
  • non-therapeutic typically means for cosmetic purposes and not curative or therapeutic purposes.
  • NHEKs normal human epidermal keratinocytes
  • Biocell, Xi’an, China were cultured in keratinocyte culture medium (KcGrowth, Biocell, Xi’an, China) and plated in 6-well plates. When the cell confluency reached 40% to 60%, the culture medium was replaced with medium together with or without actives for 24 hours. After incubation, the total RNA for each NHEK was extracted using RNAex Pro reagent (Accurate Biotechnology, Cat: AG21102) according to manufacturer’s protocol.
  • the level of the active is based on the medium. a: not significantly better (p ⁇ 0.05) than either of single active at same level. b: significantly better (p ⁇ 0.05) than either of single active at same level.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une composition de soins personnels comprenant un composé de carboxyméthyl cystéine et un composé de vitamine C, le rapport molaire du composé de carboxyméthyl cystéine au composé de vitamine C étant d'au moins 14 : 1, la composition comprenant de l'eau en une quantité de 10 à 96 % en poids de la composition.
PCT/EP2024/070948 2023-08-23 2024-07-24 Composition de soins personnels Pending WO2025040355A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023114537 2023-08-23
CNPCT/CN2023/114537 2023-08-23
EP23201727 2023-10-05
EP23201727.7 2023-10-05

Publications (1)

Publication Number Publication Date
WO2025040355A1 true WO2025040355A1 (fr) 2025-02-27

Family

ID=92106902

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/070948 Pending WO2025040355A1 (fr) 2023-08-23 2024-07-24 Composition de soins personnels

Country Status (1)

Country Link
WO (1) WO2025040355A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ15811U1 (cs) * 2005-04-22 2005-09-19 Cpn Spol. S R. O. Protivráskový kosmetický přípravek zpomalující stárnutí pokožky
US20090291931A1 (en) * 2006-08-09 2009-11-26 Polichem Sa Compositions with enhanced elasticizing activity
WO2010086736A2 (fr) * 2009-01-30 2010-08-05 Vitrupharma S.R.L. Nouvelle utilisation de la combinaison de resvératrol et de cystéine et de ses dérivés
WO2020157428A1 (fr) * 2019-01-30 2020-08-06 Lucas Meyer Cosmetics Nouvelles utilisations cosmétiques d'un extrait de rose
EP4112039A1 (fr) * 2021-07-01 2023-01-04 Unilever IP Holdings B.V. Composition cosmétique contenant un polyol, un acide organique et un composé de vitamine b5
WO2023126161A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Composition pharmaceutique ou de soins personnels

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ15811U1 (cs) * 2005-04-22 2005-09-19 Cpn Spol. S R. O. Protivráskový kosmetický přípravek zpomalující stárnutí pokožky
US20090291931A1 (en) * 2006-08-09 2009-11-26 Polichem Sa Compositions with enhanced elasticizing activity
WO2010086736A2 (fr) * 2009-01-30 2010-08-05 Vitrupharma S.R.L. Nouvelle utilisation de la combinaison de resvératrol et de cystéine et de ses dérivés
WO2020157428A1 (fr) * 2019-01-30 2020-08-06 Lucas Meyer Cosmetics Nouvelles utilisations cosmétiques d'un extrait de rose
EP4112039A1 (fr) * 2021-07-01 2023-01-04 Unilever IP Holdings B.V. Composition cosmétique contenant un polyol, un acide organique et un composé de vitamine b5
WO2023126161A1 (fr) * 2021-12-31 2023-07-06 Unilever Ip Holdings B.V. Composition pharmaceutique ou de soins personnels

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "APEROXID TLA - MakeitLab", 28 March 2024 (2024-03-28), XP093146565, Retrieved from the Internet <URL:https://www.makeitlab.eu/prodotti/materie-prime/varie/aperoxid-tla.html> [retrieved on 20240328] *
ROMAIN DUROUX ET AL., MOLECULES, vol. 25, 2020, pages 4743
SHINOBU NAKANISHI ET AL., FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 11, pages 1102585

Similar Documents

Publication Publication Date Title
ES2615338T3 (es) Utilización de microorganismos probióticos para tratar la dermatitis de contacto no alérgica
EP4456868B1 (fr) Composition de soins personnels
KR102494228B1 (ko) 효모 추출물의 신규 화장품용 및/또는 기능식품용 또는 피부과용 용도
CN116847871A (zh) 护肤组合物及其使用方法
WO2023126169A1 (fr) Utilisation d&#39;un composé de carboxyméthylcystéine
ES2693261T3 (es) Uso de derivados de C-glicósido como agentes activos pro-descamantes
TW202228748A (zh) 用於在敏感性皮膚正常化皮膚微生物群之方法與組成物
EP4456867A1 (fr) Composition pharmaceutique ou de soins personnels
WO2025040355A1 (fr) Composition de soins personnels
WO2025002724A1 (fr) Composition de soins personnels comprenant un composé de carboxyméthyl cystéine et un composé de silymarine
WO2025003016A1 (fr) Composition de soins personnels comprenant un composé de carboxyméthylcystéine et un composé de créatine
WO2025002727A1 (fr) Composition de soins personnels
WO2025002688A1 (fr) Composition de soins personnels à base d&#39;un composé de cystéine carboxyméthyle et d&#39;acide rosmarinique ou d&#39;un sel et d&#39;un ester de ceux-ci
WO2025002754A1 (fr) Composition de soins personnels
WO2025002755A1 (fr) Composition de soins personnels
EP4456863A1 (fr) Composition de soins personnels
WO2025003014A1 (fr) Composition de soins personnels à base d&#39;un composé de carboxyméthyl cystéine et d&#39;un caroténoïde ou d&#39;un ester de celui-ci
WO2025002686A1 (fr) Composition de soins personnels comprenant un composé de carboxyméthyl cystéine et un extrait du genre engelhardtia
EP4615404A1 (fr) Composition de soins personnels
EP4615398A1 (fr) Composition de soin personnel
JP2019019104A (ja) セラミド合成促進剤及び皮膚外用剤
WO2025040354A1 (fr) Composition de produits d&#39;hygiène personnelle
EP4615403A1 (fr) Composition de soins personnels
JP5225654B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有乳化組成物
EP4615402A1 (fr) Composition de soins personnels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24748380

Country of ref document: EP

Kind code of ref document: A1